FCRL 3 promotes TLR 9‐induced B‐cell activation and suppresses plasma cell differentiation
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
F c receptor‐like (FCRL) molecules are preferentially expressed by B lymphocytes and possess tyrosine‐based immunoregulatory function. Although they generally inhibit B‐cell receptor signaling, their influence on other activation pathways remains largely unexplored. In humans, FCRL 3 encodes a type I transmembrane protein harboring both cytoplasmic ITAM and ITIM elements that can repress B‐cell receptor activation. Despite this inhibitory property, mounting associations for FCRL 3 with autoimmune and lympho‐proliferative disorders imply a role for it in promoting B‐cell pathogenesis. Here, we explore the influence of FCRL3 on B‐cell responses to innate TLR 9 stimulation. A detailed survey of blood B‐cell populations found that FCRL 3 expression increased as a function of differentiation and was higher among memory subsets with innate‐like features. FCRL 3 ligation augmented C p G oligodeoxynucleotide TLR 9‐mediated B‐cell proliferation, activation, and survival, but surprisingly, abrogated plasma cell differentiation and antibody production. Although FCRL 3 amplified the NF‐κ B and mitogen‐activated protein kinase signaling cascades, it halted C p G triggered BLIMP 1 induction in an ERK‐dependent fashion. These findings indicate that FCRL 3 differentially modulates innate signaling in B cells and provide new insight into the potential of this disease‐associated receptor to counter‐regulate adaptive and innate immunity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toll-like receptors in systemic autoimmune disease
Marshak-Rothstein, A. (2006) · Nature Reviews Immunology · doi:10.1038/nri1957 · Cited by 1,116
Cited by
Portugal, S., Tipton, C. M., Sohn, H., Kone, Y., Wang, J., Li, S., Skinner, J., Virtaneva, K., Sturdevant, D. E., Porcella, S. F., et al. (2015) · eLife · doi:10.7554/elife.07218 · Cited by 329
Potential drug targets for multiple sclerosis identified through Mendelian randomization analysis
Lin, J., Zhou, J., & Xu, Y. (2023) · Brain · doi:10.1093/brain/awad070 · Cited by 271
“40,41 Consistent with our results, previous genetic studies have reported that the high producer variant of the FCRL3 gene protected against MS in Spanish and Chinese populations.”
Coexpression of TIGIT and FCRL3 Identifies Helios+ Human Memory Regulatory T Cells
Bin Dhuban, K., d’Hennezel, E., Nashi, E., Bar-Or, A., Rieder, S., Shevach, E. M., Nagata, S., & Piccirillo, C. A. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1401803 · Cited by 117
“Indeed, some studies have shown a potential role of FCRL3 in regulating B cell differentiation and proliferation initiated by BCR signaling (20, 21).”
BackgroundLi, H., Borrego, F., Nagata, S., & Tolnay, M. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1501027 · Cited by 81
“Potential activating functions were also proposed for FCRL5 (23), similarly to FCRL3 (24) and FCRL4 (25), suggesting dual regulatory capacities.”
BackgroundInfluential
Metadata
- Authors
- Li, F. J., Schreeder, D. M., Li, R., Wu, J., & Davis, R. S.
- Venue
- European Journal of Immunology
- Publisher
- Wiley
- Published
- 2013-08-12
- Volume
- 43
- Issue
- 11
- Pages
- 2980-2992
- ISSN
- 0014-2980 (ISSN-L)
- 1521-4141
- OpenAlex
- W1989708237
- Cited by
- 84
- References
- 1
- FWCI
- 2.20
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: FCRL 3 promotes TLR 9‐induced B‐cell activation and suppresses plasma cell differentiation. https://app.cochat.ai/papers/10.1002/eji.201243068
- The paper
- Li, F. J., Schreeder, D. M., Li, R., Wu, J., & Davis, R. S. (2013). FCRL 3 promotes TLR 9‐induced B‐cell activation and suppresses plasma cell differentiation. European Journal of Immunology. https://doi.org/10.1002/eji.201243068
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.